<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> type 2 and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> are the risk factors for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>It is already known that <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> is an <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e>, and a lot of different factors are involved in its <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>C-<z:chebi fb="7" ids="16670">peptide</z:chebi> is a cleavage product of proinsulin, an active substance with a number of effects within different complications of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In this paper we discuss the role of C-<z:chebi fb="7" ids="16670">peptide</z:chebi> and its effects in the development of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> in type 2 diabetic patients </plain></SENT>
</text></document>